<PAGE>

                                                                    EXHIBIT 99.1
FOR IMMEDIATE RELEASE

Contact:
Gregory A. Marsh                        Michelle D. Getty
Vice President & CFO                    Investor Relations
AmeriPath, Inc.                         AmeriPath, Inc.
561-712-6211                            561-712-6260
                                        E-mail:  invrel@ameripath.com

                   AMERIPATH, INC. COMMENTS ON TRAGIC EVENTS

Riviera Beach, FL, September 21, 2001 - AmeriPath, Inc. (Nasdaq:PATH), the
largest physician and laboratory company focused on providing anatomic
pathology, cancer diagnostic, genomics, and healthcare information services,
today announced that as a result of the tragic events that occurred in New York
City, Washington, D.C., and near Pittsburgh, Pennsylvania on September 11th, the
Company expects net revenue to be negatively impacted resulting in an EPS
shortfall for the third quarter and the year of approximately $.02 to $.04 per
share from our previous guidance.

AmeriPath's Chairman and Chief Executive Officer, James C. New, commented, "We
have all been touched in some way by this terrible tragedy, and on behalf of the
Company, extend our deepest condolences to the people whose lives have been
affected by these atrocious events.  The Company is actively participating in
fund raising and relief activities."

Mr. New further commented, "Due to the temporary disruption in general
transportation, both land and air, combined with a significant disruption to our
New York City area business for a few days, we expect revenues will be $1.5
million to $2.5 million short of target for the third quarter and the year.  We
believe these are one-time revenue losses as our overall company volume has now
recovered to normal levels.  We continue to be optimistic for the balance of
2001 and 2002 as our long-term strategic plans are producing solid results."

The statements contained in this press release include "forward-looking
statements'' within the meaning of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements - which are sometimes identified by words
such as "may", "should", "believe'', "expect'', "anticipate'', "estimate" and
similar expressions and which include any financial or operating estimates,
forecasts or projections - are subject to a number of risks and uncertainties,
many of which involve factors or circumstances that are beyond the Company's
control. These risks and uncertainties could cause actual results to differ
materially from historical results or from results anticipated by forward-
looking statements. These risks and uncertainties include: the extent of success
of the Company's operating initiatives and growth strategies; ability to manage
growth; access to capital on satisfactory terms; general economic conditions; a
possible outbreak of hostilities or war; competition and changes in competitive
factors; federal and state healthcare regulation (and compliance); reimbursement
rates under government and third party healthcare programs and the payments
received under such programs; changes in coding; changes in technology;
dependence upon pathologists and customer contracts; the ability to attract,
motivate, and retain pathologists; labor and technology costs; marketing and
promotional efforts; the availability of pathology practices in appropriate
locations that the Company is able to acquire on suitable terms or develop; the
successful completion and integration of acquisitions (and achievement of
planned or expected synergies); and tax laws. The forward-looking statements in
this press release are made as of the date hereof based on management's current
beliefs and expectations, and the Company undertakes no obligation to update or
revise any such statements, whether as result of new developments, new
information or otherwise. Further information regarding risks, uncertainties and
other factors that could affect the Company's financial or operating results or
that could cause actual results to differ materially from those expected,
estimated or anticipated are included in the Company's annual, quarterly, and
other reports and filings with the SEC. Past performance is not necessarily
indicative of future results.

   Editor's Note: This release is also available at http://www.ameripath.com
                                                    ------------------------

